Tsai‐Sheng Yang

8.0k total citations
37 papers, 733 citations indexed

About

Tsai‐Sheng Yang is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tsai‐Sheng Yang has authored 37 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Hepatology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tsai‐Sheng Yang's work include Colorectal Cancer Treatments and Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Gastric Cancer Management and Outcomes (8 papers). Tsai‐Sheng Yang is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Gastric Cancer Management and Outcomes (8 papers). Tsai‐Sheng Yang collaborates with scholars based in Taiwan, China and South Korea. Tsai‐Sheng Yang's co-authors include Hung‐Chih Hsu, Ann‐Lii Cheng, Shu‐Jen Chen, Hua‐Chien Chen, Giuseppe Lentini, Won Young Tak, Hongming Pan, Shukui Qin, Jun Suk Kim and Zhongzhen Guan and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Journal of Hepatology.

In The Last Decade

Tsai‐Sheng Yang

35 papers receiving 723 citations

Peers

Tsai‐Sheng Yang

ONCOL

HEPAT

PFM

E Popa United States

Donald Poon Singapore

Monica Lencioni Italy

Koji Miyahara Japan

Wai Meng David Tai Singapore

Martina Valgiusti Italy

Toru Hisaka Japan

Qinguo Mo China

Hideki Ueno Japan

Tatsuya Orimo Japan

E Popa United States

Tsai‐Sheng Yang

238 ×0.8

ONCOL

298 ×1.0

HEPAT

191 ×1.0

180 ×1.1

PFM

101 ×0.7

Citations per year, relative to Tsai‐Sheng Yang Tsai‐Sheng Yang (= 1×) peers E Popa

Countries citing papers authored by Tsai‐Sheng Yang

Since Specialization

Citations

This map shows the geographic impact of Tsai‐Sheng Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsai‐Sheng Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsai‐Sheng Yang more than expected).

Fields of papers citing papers by Tsai‐Sheng Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsai‐Sheng Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsai‐Sheng Yang. The network helps show where Tsai‐Sheng Yang may publish in the future.

Co-authorship network of co-authors of Tsai‐Sheng Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Tsai‐Sheng Yang. A scholar is included among the top collaborators of Tsai‐Sheng Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsai‐Sheng Yang. Tsai‐Sheng Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hsu, Hung‐Chih, Wen‐Hung Chung, Yung‐Chang Lin, et al.. (2024). Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions. Allergology International. 73(4). 580–586. 3 indexed citations

Yang, Tsai‐Sheng, Hong‐Hwa Chen, Tae Won Kim, et al.. (2023). Prospective, open‐label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study. Asia-Pacific Journal of Clinical Oncology. 19(6). 672–680.

Lu, Chun‐Wei, Chun‐Nan Yeh, Hung‐Chih Hsu, et al.. (2023). Zinc supplementation is associated with improvement in hand-foot skin reaction in patients on vascular endothelial growth factor receptor-tyrosine kinase inhibitors: A cohort study. Journal of the American Academy of Dermatology. 90(4). 814–815. 2 indexed citations

Huang, Wen‐Kuan, Hung‐Chih Hsu, Tsai‐Sheng Yang, et al.. (2023). Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. European Journal of Cancer. 195. 113286–113286. 1 indexed citations

Shao, Yu‐Yun, Yin‐Hsun Feng, Chia‐Jui Yen, et al.. (2022). Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety. Journal of the Formosan Medical Association. 121(12). 2430–2437. 9 indexed citations

Yeh, Kun‐Huei, Tsai‐Sheng Yang, Tzu‐Chi Hsu, et al.. (2021). Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. Journal of the Formosan Medical Association. 120(11). 2023–2031. 9 indexed citations

Hsu, Hung‐Chih, Wei-Shone Chen, Jeng‐Kai Jiang, et al.. (2021). Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. Scientific Reports. 11(1). 15370–15370. 2 indexed citations

Galle, Peter R., Masatoshi Kudo, Josep M. Llovet, et al.. (2020). Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2. Journal of Hepatology. 73. S386–S387. 1 indexed citations

Hsu, Hung‐Chih, Wen-Chi Chou, Feng-Che Kuan, et al.. (2018). A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients. Cancer Management and Research. Volume 10. 6061–6070. 2 indexed citations

10.

Chou, Wen‐Chi, Chia-Lin Lee, Tsai‐Sheng Yang, et al.. (2017). Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. Journal of the Formosan Medical Association. 117(2). 153–163. 22 indexed citations

11.

Hsu, Hung‐Chih, Yen‐Jung Lu, Chien Yuh Yeh, et al.. (2016). Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget. 7(16). 22257–22270. 97 indexed citations

12.

Liu, Feng‐Yuan, Tzu‐Chen Yen, Jeng‐Yi Wang, & Tsai‐Sheng Yang. (2015). Early Prediction by 18F-FDG PET/CT for Progression-Free Survival and Overall Survival in Patients With Metastatic Colorectal Cancer Receiving Third-Line Cetuximab-Based Therapy. Clinical Nuclear Medicine. 40(3). 200–205. 21 indexed citations

13.

Hsu, Hung‐Chih, Yi‐Shiuan Liu, Tsai‐Sheng Yang, et al.. (2014). CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression. Journal of Cancer Research and Clinical Oncology. 141(1). 11–21. 24 indexed citations

14.

Chen, Jen‐Shi, Wen-Chi Chou, Chi‐Ting Liau, et al.. (2013). Modified Biweekly Oxaliplatin and Capecitabine for Advanced Gastric Cancer: A Retrospective Analysis from a Medical Center. Biomedical Journal. 0(0). 0–0. 7 indexed citations

15.

Huang, Wen‐Kuan, Yung‐Chang Lin, Meng‐Jiun Chiou, et al.. (2013). Pyogenic Liver Abscess as a Warning Sign for Primary Liver Cancer: A Nationwide Population-based Study. Asian Pacific Journal of Cancer Prevention. 14(8). 4727–4731. 6 indexed citations

16.

Hsu, Hung‐Chih, Yi‐Shiuan Liu, Cheng–Lung Hsu, et al.. (2013). Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. International Journal of Colorectal Disease. 28(11). 1535–1546. 73 indexed citations

17.

Cheng, Ann‐Lii, Gerardo Cornelio, Lin Shen, et al.. (2013). First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study. Annals of Oncology. 24. iv34–iv35. 4 indexed citations

18.

Hsu, Chiun, Tsai‐Sheng Yang, Teh‐Ia Huo, et al.. (2012). Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology. 56(5). 1097–1103. 83 indexed citations

19.

Cheng, Ann‐Lii, Zhongzhen Guan, Zhendong Chen, et al.. (2012). Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial. European Journal of Cancer. 48(10). 1452–1465. 222 indexed citations

20.

Su, Po‐Jung, et al.. (2011). Leptomeningeal Carcinomatosis from a Primary Colon Cancer Patient. 27(3). 113–116. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact